分子靶向抗血管生成药物在晚期肺癌治疗中的心脏和血管风险  

Cardiac and vascular risks of anti-angiogenic TKIs used in the treatment of advanced lung cancer

作　　者：薛崇祥 鲁星妤 董慧静 陈颖[1,3] 芦瑞霞[1,4] 姚婷婷 张静怡 崔慧娟 XUE Chongxiang;LU Xingyu;DONG Huijing;CHEN Ying;LU Ruixia;YAO Tingting;ZHANG Jingyi;CUI Huijuan(Beijing University of Traditional Chinese Medicine,Beijing 100029,China;Department of Integrative Oncology,National Clinical Research Center for Respiratory Diseases,Center of Respiratory Medicine,China-Japan Friendship Hospital,Beijing 100029,Chin;Department of Integrative Cardiology,National Clinical Research Center for Respiratory Diseases,Center of Respiratory Medicine,China-Japan Friendship Hospital,Beijing 100029,China;Cardiovascular Disease Center,Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing 100091,China;First Cardiovascular District,Dongzhimen Hospital,Beijing University of Traditional Chinese Medicine,Beijing 100700,China)

机构地区：[1]北京中医药大学,北京100029 [2]国家呼吸疾病临床研究中心/中日友好医院呼吸中心中西医结合肿瘤内科,北京100029 [3]国家呼吸疾病临床研究中心/中日友好医院呼吸中心中西医结合心脏内科,北京100029 [4]中国中医科学院西苑医院心血管病中心,北京100091 [5]北京中医药大学东直门医院心血管一区,北京100700

出　　处：《现代肿瘤医学》2022年第7期1322-1327,共6页Journal of Modern Oncology

基　　金：国家自然科学基金项目(编号:81873396);首都卫生发展科研专项(编号:2018-2-4065);中日友好医院横向课题(编号:2018-HX-36)。

摘　　要：分子靶向抗血管生成药物使越来越多的肺癌患者在临床试验和真实世界研究中受益,多种抗血管生成药物已被批准用于晚期肺癌的临床治疗,逐渐成为不可或缺的肺癌治疗方式之一。然而,与抗血管生成治疗相关的潜在心脏和血管不良反应可能会严重影响患者的生活质量,导致治疗药物减量甚至停药,并因此影响抗肿瘤治疗效果。高血压(hypertension,HTN)、左心室功能减低、血栓栓塞和出血是抗血管生成酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)最常见的心脏和血管不良反应。因此,患者心脏、血管基线状况和相关并发症的临床评估相当重要,可用于确认风险等级,帮助制定相关风险预防计划。Anti-angiogenic TKIs are effective cancer therapeutic drugs which inhibit multiple signal pathways.An important proportion of patients with malignancies have benefited from those indispensable agents in different clinical trials.Several targeted drugs have been approved for the treatment of advanced lung cancer.However,potential serious cardiac and vascular adverse events related to anti-angiogenic targeted therapy might severely affect quality of life and cause dose reduction.Hypertension,left ventricular insufficiency,thromboembolism and hemorrhage events are the most frequent cardiac and vascular adverse effects of this kind of anticancer agents.As such,clinical assessment of the patient's cardiac and vascular condition and co-morbidities can be used to confirm the risk grades and help develop preventive schedules.

关 键 词：分子靶向 抗血管生成药物 心脏风险 血管风险 晚期肺癌 临床管理 

分 类 号：R734.2[医药卫生—肿瘤]